Composition for prevention or treatment of neurofibromatosis type 2 syndrome
AssigneePrg S&Tech Inc.
InventorsBum-Joon Park, Hwayoung Yun
Life of this patent
Estimating the term…
Abstract
The present invention relates to a composition for prevention or treatment of neurofibromatosis type 2 syndrome, wherein in contrast to the conventional TβR1 kinase inhibitor TEW7197, the compound represented by chemical formula 1, a pharmaceutically acceptable salt thereof, a solvate thereof, a stereoisomer thereof, or a combination thereof according to the present invention suppresses TGF-β receptor 1 (TβR1)-mediated RKIP reduction while not inhibiting normal TGF-β signaling and thus, can be used as a novel form of a therapeutic agent for neurofibromatosis type 2 syndrome, which can solve the side effect problem caused by the inhibition of normal TGF-β signaling.
Claims5
A compound selected from a compound represented by the following Chemical Formula 1, a pharmaceutically acceptable salt thereof, a solvate thereof, or a stereoisomer thereof:
- wherein, in the Chemical Formula 1,
- R1 is NR5R6 or CN, R5 or R6 is the same or different respectively and hydrogen or (C1~C4)alkyl,
- R2 is halo, (C1~C4)alkyl, or (C1~C4)alkoxy,
- R3 or R4 is the same or different respectively and hydrogen, (C1~C4)alkyl, or (C1~C4)alkoxy, and
- n is an integer of 0 to 3.
A method of preventing or treating neurofibromatosis type 2 (NF2) syndrome in a subject, comprising:
- administering a pharmaceutical composition comprising a compound selected from a compound represented by the following Chemical Formula 1, a pharmaceutically acceptable salt thereof, a solvate thereof, or a stereoisomer thereof to the subject:
- wherein, in the Chemical Formula 1,
- R1 is NR5R6 or CN, R5 or R6 is the same or different respectively and hydrogen or (C1~C4)alkyl,
- R2 is halo, (C1~C4)alkyl, or (C1~C4)alkoxy,
- R3 or R4 is the same or different respectively and hydrogen, (C1~C4)alkyl, or (C1~C4)alkoxy, and
- n is an integer of 0 to 3.
A method of preventing or ameliorating neurofibromatosis type 2 (NF2) syndrome in a subject, comprising:
- administering a health food composition comprising a compound selected from a compound represented by the following Chemical Formula 1, a pharmaceutically acceptable salt thereof, a solvate thereof, or a stereoisomer thereof to the subject:
- wherein, in the Chemical Formula 1,
- R1 is NR5R6 or CN, R5 or R6 is the same or different respectively and hydrogen or (C1~C4)alkyl,
- R2 is halo, (C1~C4)alkyl, or (C1~C4)alkoxy,
- R3 or R4 is the same or different respectively and hydrogen, (C1~C4)alkyl, or (C1~C4)alkoxy, and
- n is an integer of 0 to 3.
Dependencies are inferred from the claim text.